TMEM61: A Potential Drug Target and Biomarker (G199964)

Target Name: TMEM61

NCBI ID: G199964

TMEM61

Other Name(s): Transmembrane protein 61 | transmembrane protein 61 | TMM61_HUMAN

TMEM61: A Potential Drug Target and Biomarker

TMEM61, short for tricalcium malate endonuclease 61, is a protein that is expressed in various tissues of the body, including the brain, heart, and pancreas. It is a key enzyme in the regulation of cell signaling, specifically in the regulation of neurotransmitter release. The dysfunction of TMEM61 has been implicated in a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. As such, TMEM61 has emerged as a promising drug target and biomarker for the development of new treatments for these disorders.

TMEM61 is a member of the N-terminal subfamily of the superfamily of N-acetyltransferases (NATs), which are a group of enzymes that are involved in the transfer of acetyl groups to various biomolecules, including proteins, nucleic acids, and lipids. The N-terminal subfamily of NATs includes a number of different enzymes, including TMEM61, which is characterized by the presence of a single catalytic active site and a distinct N-terminal region that is involved in the transfer of acetyl groups to other molecules.

TMEM61 is expressed in a variety of tissues and cells of the body, including the brain, heart, and pancreas. It is highly expressed in the brain, where it is present in the basal ganglia, the primary motor cortex, and other regions. It is also expressed in the heart and pancreas, where it is involved in the regulation of ion channels and other physiological processes.

The dysfunction of TMEM61 has been implicated in a number of neurological and psychiatric disorders. For example, TMEM61 has been shown to be involved in the regulation of neurotransmitter release in the brain, with studies suggesting that it plays a role in the regulation of dopamine release. In addition, TMEM61 has been implicated in the regulation of ion channels in the heart, with studies suggesting that it plays a role in the regulation of atrial and sodium channels.

As a result of its involvement in these processes, TMEM61 has been shown to be a promising drug target and biomarker for the development of new treatments for neurological and psychiatric disorders. One approach to targeting TMEM61 is to use small molecules that can modulate its activity, such as inhibitors of NATs that are known to interact with TMEM61. These molecules can be administered to the body and are designed to specifically target TMEM61, rather than other NATs. This approach has the potential to reduce the risk of unintended side effects associated with traditional drug treatments.

Another approach to targeting TMEM61 is to use antibodies that are designed to recognize and target specific regions of the protein. These antibodies can be administered to the body and are designed to specifically bind to TMEM61, rather than other proteins. This approach has the potential to provide more targeted and effective treatments for TMEM61-related disorders.

In addition to its potential as a drug target, TMEM61 is also a promising biomarker for the diagnosis and progression of neurological and psychiatric disorders. For example, studies have shown that TMEM61 is often reduced in the brains of individuals with Alzheimer's disease, and that its levels are increased in the brains of individuals with Parkinson's disease. These findings suggest that TMEM61 may be a useful biomarker for the diagnosis and progression of these disorders.

Overall, TMEM61 is a protein that is involved in the regulation of cell signaling in various tissues of the body. Its dysfunction has been implicated in a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. As such, TMEM61 has emerged as a promising drug target and biomarker for the development of new treatments for these disorders. Further research is needed to fully understand the role of TMEM61 in these processes and to develop effective treatments.

Protein Name: Transmembrane Protein 61

The "TMEM61 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM61 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets